TESARO Inc (NASDAQ:TSRO) was the target of some unusual options trading on Friday. Stock investors purchased 4,766 call options on the stock. This represents an increase of 1,698% compared to the typical volume of 265 call options.
In related news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 34.60% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its position in shares of TESARO by 8.1% during the 3rd quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after purchasing an additional 29,100 shares in the last quarter. TimesSquare Capital Management LLC bought a new position in shares of TESARO during the 3rd quarter worth about $33,911,000. Tobam bought a new position in shares of TESARO during the 2nd quarter worth about $20,189,000. Sphera Funds Management LTD. bought a new position in shares of TESARO during the 2nd quarter worth about $7,692,000. Finally, Fiera Capital Corp bought a new position in shares of TESARO during the 2nd quarter worth about $18,451,000.
Shares of TESARO (TSRO) traded down $4.33 on Thursday, reaching $71.66. 1,545,103 shares of the company’s stock were exchanged, compared to its average volume of 1,011,073. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $3,940.00, a PE ratio of -8.50 and a beta of 1.51. TESARO has a twelve month low of $71.50 and a twelve month high of $192.94.
TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The business’s revenue was up 740.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.72) EPS. research analysts forecast that TESARO will post -8.19 EPS for the current fiscal year.
Several research analysts have commented on TSRO shares. Barclays started coverage on shares of TESARO in a research report on Monday, October 23rd. They set an “equal weight” rating and a $135.00 price objective for the company. ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group restated a “hold” rating and set a $124.00 price objective on shares of TESARO in a research report on Friday, November 3rd. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of TESARO in a research report on Thursday, October 26th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $165.00 price target (down from $181.00) on shares of TESARO in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $152.64.
COPYRIGHT VIOLATION NOTICE: “TESARO Target of Unusually High Options Trading (TSRO)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/stock-traders-buy-high-volume-of-tesaro-call-options-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.